The content on this site is intended for healthcare professionals only
Dr Fredrik Schjesvold speaks to ecancer about results from the OCEAN study that he presented at EMN 2024.
He explains that this is a phase III study where patients were randomised 1:1 between melflufen and dexamethasone versus pomalidomide and dexamethasone with the primary endpoint being PFS.
Dr Schjesvold reports that the results were quite complicated. Initial findings showed an improvement in PFS with melflufen and dexamethasone but a slight improvement in OS with pomalidomide and dexamethasone.
However a closer look at the data showed that non-transplant patients were the ones seeing the greatest benefit from the new treatment - leading to an approval of the drug in non-transplant patients.
Independent clones in CLL show oligoclonality and early evolution patterns
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
